Accepted Manuscript

Title: Pharmacogenetics and application in pediatrics

Author: Virginia Neyro Evelyne Jacqz-Aigrain Tiphaine

Adam de Beaumais

PII: S0040-5957(18)30015-5

DOI: https://doi.org/doi:10.1016/j.therap.2017.11.010

Reference: THERAP 245

To appear in:

Received date: 15-10-2017 Accepted date: 15-11-2017

Please cite this article as: Virginia NeyroEvelyne Jacqz-AigrainTiphaine Adam de Beaumais Pharmacogenetics and application in pediatrics (2018), https://doi.org/10.1016/j.therap.2017.11.010

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Therapie

Rubrique: Pediatric pharmacology/Drugs and children

Numéro 2 mars avril 2018

Pharmacogenetics and application in pediatrics Pharmacogenetics and application in pediatrics

Virginia Neyro^a, Evelyne Jacqz-Aigrain^{a,b,c}, Tiphaine Adam de Beaumais^{a,d*}

Received 15 October 2017; accepted 15 November 2017

*Corresponding author. Department of pediatric pharmacology and pharmacogenetics, Robert Debré Hospital, 48 boulevard Sérurier, 75019 Paris, France.

E-mail adress: tiphaine.debeaumais@aphp.fr

Summary

Identification of markers involved in drug disposition is crucial for drugs with a narrow therapeutic index. Individual genomic differences can affect the pharmacology of some drugs and participate to inter-individual variability in drug response. Pharmacogenetics is a useful tool in clinical practice for dosage adjustment and to limit drug toxicities. In pediatrics, physiological changes can also influence the disposition of drugs in infants, children and adolescents. The importance of ontogeny translates into different responses to the same drug in children and adults. Thus, interactions between the maturation of metabolism enzymes or transporters and genetics have a major impact on drug exposure leading to age-specific dosage requirements. This review aims to describe implementation of pharmacogenetics in personalized medicine and specifies pediatric characteristics with ethical considerations.

KEYWORDS

Genetics; Pediatrics; Pharmacology

Abbreviations

6-MP: 6-mercaptopurine

6-MMPN: 6- methylmercaptopurine nucleotides

6-TGN: 6-thioguanine

CPIC®: Clinical pharmacogenetics implementation consortium

CYP2D6: CYP450 family 2 subfamily D type 6

^a Department of paediatric pharmacology and pharmacogenetics, Robert Debré Hospital, AP-HP, 75019 Paris, France

^b University of Paris Diderot Sorbonne Paris Cité, 75013 Paris, France

^c Clinical investigation center CIC1426, INSERM, 75019 Paris, France

^d Precision cancer medicine team, Gustave Roussy, 94800 Villejuif, France

Download English Version:

https://daneshyari.com/en/article/8544284

Download Persian Version:

https://daneshyari.com/article/8544284

<u>Daneshyari.com</u>